guidanc reset bar copiktra materi launch
headwind target
verastem announc financi result focus modest
sale guidanc copiktra novel oral delta/gamma inhibitor
well estim maintain
patienc need verastem work overcom challeng
percept class guidanc suggest like
take longer anticip result lower copiktra sale
estim remov near-term potenti npv analysi
collect lower vstm target
revis copiktra sale estim modestli
guidanc believ launch follicular lymphoma
fulli underway recent benefit also lower us
copiktra sale estim
also moder us peak sale potenti
approv cll/sll fl indic also
ptcl potenti label expans initi data copiktra earli
stage data r/r patient show encourag respons
treat copiktra combo copiktra romidepsin achiev orr
median month orr
current therapi verastem current
enrol phase primo studi copiktra monotherapi r/r
patient enrol proceed well data could come
op copiktra sale estimate op ex
larg in-lin ep estimate
copiktra launch dynam initi traction measur
demograph treatment trend favor copiktra cll estim
could reach indic though smaller indic
cll fl patient could earli adopt copiktra unmet
need refractori fl set materi imbruvica venclexta
reimburs larg place manag focus
expect term toler molecul
vstm valuat target lower estim vstm stand-
alon npv remov formal potenti
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
verastem biopharmaceut compani headquart needham mass
focus develop cancer therapeut advanc
program copiktra duvelisib defactinib progress clinic studi
multipl indic exhibit copiktra verastem materi asset
first-in-class molecul target phosphoinositid
central signal pathway cancer prolifer surviv
copiktra novel dual inhibit delta gamma isoform
copiktra directli attack malign b-cell t-cell believ
materi disrupt tumor microenviron copiktra approv
septemb line cll/sll line fl
exhibit verastem pipelin copiktra duvelisib defactinib focus
copiktra highli activ relapsed/refractori cll/sll follicular
lymphoma yield fda prioriti review dual delta
gamma inhibit activ copiktra demonstr solid activ
number set produc encourag result sever trial includ
duo phase studi patient relaps refractori chronic
sll
dynamo phase monotherapi studi patient refractori indol non-
hodgkin lymphoma inhl copiktra abl demonstr rapid
statist signific clinic meaning activ cll/sll duo
mo vs mo compar hr exhibit
overal studi popul well robust respons
challeng delet subpopul mo copiktra
vs mo compar hr impress result
patient gener limit respons older therapeut
exhibit copiktra posit perform phase duo studi
relapsed/
cll/sll
duo led
review
respons
lymphoma
copiktra attain orr follicular lymphoma fl patient lead
toward potenti acceler approv final analysi
patient fl cohort dynamo copiktra overal respons rate orr
cr measur irc exhibit blue bar fl patient studi
rapid time respons median month durat
respons median progression-fre surviv month overal
surviv os month appear meaning result
patient refractori rituximab chemo/rit
ibrutinib appear effect given unmet need refractori
follicular lymphoma copiktra efficaci molecul receiv acceler
approv fda set septemb believ fl
patient could earli adopt copiktra therapi treatment option
limit relapsed/refractori fl set
exhibit copiktra posit perform dynamo waterfal plot
copiktra close transform verastem prioriti review underscor
potenti data duo dynamo support copiktra us licensur
septemb ahead octob pdufa date februari
verastem submit nda copiktra seek full approv molecul
relapsed/refractori cll/sll acceler approv relapsed/
refractori follicular lymphoma fl copiktra nda accept
prioriti review establish octob pdufa june duvelisib
licens yakult honsha rate develop
commerci japanes market septemb licens
double-
lymphoma
acceler
approv
set
note
duvelisib
coliti
rate
idelalisib
cspc china licens geographi possibl copiktra
evalu earlier line therapi cll fl indic combin
multipl agent begun see initi posit data emerg
expect work area beyond cll fl copiktra also
develop peripher t-cell lymphoma anoth set materi
unmet need molecul shown promis activ earli clinic
work us licensur expect interest duvelisib materi increas
public present activ profil continu emerg
exhibit copiktra posit perform dynamo solid result
copiktra novel dual inhibit copiktra select target
delta gamma isoform phosphoinositid key
element central signal pathway involv cancer prolifer
surviv dual inhibit copiktra believ
directli attack malign b-cell t-cell also disrupt tumor
micro-environ specif nearli exclus express
hematopoiet cell hyperact b-cell malign promot
b-cell prolifer growth surviv adhes home inhibit
demonstr activ variou b-cell leukemia lymphoma
intriguingli also reduc immuno-suppress treg highli express
myeloid cell activ appear associ increas
stabil tumor microenviron inhibit appear abl
reshap tumor immun microenviron promot tumor regress
without target cancer cell directli result find
copiktra dual inhibit activ develop work consider
copiktra combin checkpoint inhibitor
separ sever toxic seen select
inhibitor manag copiktra clearli focu
verastem good complianc prophylaxi regimen manag
infect risk recent intens focu ae manag evolv
broader adopt io therapeut believ effect
address verastem addit cll kol believ copiktra
inhibit may materi decreas sever unpredict immun
mediat toxic coliti etc appear select
revenu
reach
us
across
time
built
market dynam cll fl provid materi room copiktra
importantli market dynam cll appear favor toward
accept copiktra later line therapi imbruvica ibrutinib move
toward front-lin consider materi number patient
experienc resist molecul toler issu
element creat room relapsed/refractori set
copiktra addit venclexta also approv refractori set
also signific challeng toler suffer
conveni issu hospit dose ramp week fl
rel lack efficaci agent later line provid materi
room copiktra initi indic relapsed/refractori cll/sll
fl copiktra potenti simpl oral monotherapi typic elderli cancer
patient believ result materi consider along ptcl
possibl use variou combin cll/fl therapi
even io therapeut copiktra revenu potenti could exceed
us peak across indic row
fak inhibitor defactinib progress verastem multipl studi
on-going evalu defactinib focal adhes kinas fak inhibitor
combin approv therapeut fak activ variou
tumor shown drive exhaust cell recruit
treg tumor microenviron among effect permit
enhanc growth fak-express tumor fak inhibit therefor
potenti creat favor tumor microenviron anti-canc
therapi checkpoint inhibitor verastem conduct phase trial
antibodi bavencio avelumab ovarian cancer
washington univers school medicin cancer research uk
conduct earli phase trial antibodi keytruda
pembrolizumab nsclc pancreat cancer mesothelioma
washington univers present encourag phase data defactinib
keytruda gemcitabin advanc cancer patient show pr
stabl diseas pancreat ductal carcinoma pdac patient
diseas control rate pdac support move tripl combin
pdac expans cohort recommend phase dose though earli
clinic set defactinib demonstr meaning proof-of-
concept program could establish materi potenti offer substanti
upsid vstm share
verastem corpor strategi capabl verastem cannili acquir
right copiktra infin pharmaceut attract econom
latter compani bit corpor pickl posit data readout
quit benefici verastem verastem prepar copiktra
upcom commerci launch commit market molecul
us partnership outsid us recent ink deal yakult
japan expect addit agreement eu asian
countri well approv us septemb
commerci verastem us commerci infrastructur
verastem vstm share valuat verastem oper
potenti signific revenu earn variabl come
quarter year result valu oper use fully-tax risk-
weight npv methodolog major asset calcul npv estim
use vstm share million verastem advanc proprietari
asset copiktra relaps refractori cll/sll double-refractori fl
potenti indic repres bulk valu
verastem oper view activ oncolog sector
remain on-going remov formal take-over potenti model
time
copiktra valuat estim copiktra next-gener twice-
daili oral inhibitor approv fda verastem valuabl
asset believ materi potenti low-burden twice-daili oral
monotherapi market refractori patient look continu care
commun set cll fl indic estim peak us
revenu million copiktra across indic million cll
fl verastem direct clinic develop molecul broaden
label composit matter patent protect estim
potenti extens possibl beyond copiktra current estim
estim valu asset verastem also
consid addit assumpt verastem licens molecul
partner variou intern geographi
defactinib valuat defactinib demonstr potenti improv
tumor microenviron current evalu combin
solid tumor indic earli activ shown
pdac defactinib profil translat meaning clinic benefit
could signific potenti molecul solid tumor signific
upsid npv calcul high risk current valu
defactinib
asset verastem pro-forma net cash includ
cash plu million drawn term loan april less
outstand pro-forma debt convert note
nol asset drag gener corpor oper
expens total share yield total treat convert
note debt stand-alone calcul
copiktra licens infin pharmaceut copiktra verastem
registration-stag oral dual inhibitor isoform delta gamma
licens infin pharmaceut intellikin divis takeda
tkppi rate along asset
announc close ipo million share common stock
per share aggreg net proce approxim million
fund continu develop earli stage therapeut companion
juli verastem licens defactinib verastem enter
exclus licens agreement rate research develop
manufactur commerci focal adhes kinas fak inhibitor
includ defactinib therapeut diagnost
prophylact use human fak inhibitor thought block
transcript chemokin recruit regulatori cell creat
up-front issu common share elig
million development mileston addit million
regulatori sale mileston high-singl mid double-digit royalti
futur net sale
licens infin pharmaceuticalsinfin licens duvelisib profit share ipo rais develop cancer stem licens defactinib assetsasset initi target achiev posit phase volunteerssupport develop duo studi duvelisib r/r cll/sll initiatesdata basi nda licens oncolog up-front mileston us profit registration-direct studi terminatescommand trial mesothelioma stop fulli enrol phase dynamo studi nhlorr data support acceler approv initi corpor restructuringreduc headcount reciev fda track r/r cll fl track facilit develop interact miss phase autoimmun studiesdevelop pivot sole oncolog initi io collaborationsevalu ovarian pancreat cancersvvvsep temin duvelisib collaborationright return infi paid totalvvvvnov in-licens duvelisib infiphas asset mileston royaltyvvvvvdec dynamo data oral present demonstr meaning orr acceler appov vvvvvjun long-term follow-up data icml ehaimprov orr in-lin safeti grant fda track r/r track facilit develop interact w/fdavvvvoct guidanc duvelisib nda submissioninform nda submiss strategyvvvvdec phase duo data oral present irc manag safeti profil support ndavvvvvdec phase data tcl oral present support developmentvvvvdec equiti financingproce fund precommerci effortsvvvvjan hercul debt facil addit fundingvvvvfeb nda submittedseek full approv r/r cll/sll acceler approv fl vvvvfeb phase result publish bloodpubl drive awar medic initi phase brio studyenrol btk-experienc cll/sll initi phase primo studyenrol r/r pt posit data expand labelvvvapr nda accept prioriti reviewvalid potenti duvelisib address unmet needvvvvvjun present abstract ascoaddit duvelisib data defactinib/keytruda pancreaticvvvvjun partner up-front mileston double-digit royaltiesvvvvjun eha meetingor present earli cll biomark equiti capit offer atm fund pre-commerci activitiesvvvv signific least import vvvvv import
copiktra phase result phase safeti data healthi subject
present medic confer copiktra singl dose
multipl dose twice
daili daili assess copiktra pharmacokinet dose-
depend achiev concentr suffici potenti
inhibit dose copiktra safeti line placebo
verastem rais million juli verastem announc
close million share common stock total net
proce million fund defactinib clinic develop
phase duo trial initi relapsed/refractori chronic
phase duo trial enrol relapsed/refractori cll/sll patient receiv
either twice daili oral copiktra dose continu iv ofatumumab
standard-of care iv day iv weekli week
monthli month crossov trial design allow patient progress
either arm cross patient requir receiv
pneumocysti prophylaxi cmv prophylaxi recommend
primari endpoint secondari endpoint includ orr durat
respons os safeti also evalu elig requir prior anti-
cancer therapi hemoglobin least platelet count
higher independ transfus support minimum absolut
neutrophil count patient prior btk inhibitor exclud
posit data present oral present
duvelisib licens oncolog use duvelisib
licens
infin rate develop
commerci oncolog use term million up-front
addit million mileston us profit share royalti
intern sale made total payment infin million
termin agreement septemb
price million common share per share aggreg net
proce approxim million fund defactinib clinic program
includ registration-direct command studi mesothelioma
phase trial patient kras-mut nsclc
aug copiktra grant fda track design relapsed/
refractori cll track design facilit develop drug
treat seriou condit fill unmet medic need design
help facilit verastem interact agenc may help
expedit on-going nda review process copiktra fda ema orphan
drug design indic
sep defactinib command studi stop due futil verastem
termin defactinib command trial malign pleural mesothelioma
due differ defactinib versu placebo popul
patient merlin-low tumor registration-direct random
double-blind placebo-control command studi evalu defactinib
switch mainten treatment patient malign pleural
mesothelioma benefit frontlin therapi
sep public highlight posit effect fak inhibit
tumor micro environ preclin studi publish cell show
activ fak accumul nucleu tumor cell promot immun
escap fak facilit transcript chemokin cytokin
encourag develop
environ data support assess fak
combin cell stimulatori therapeut
copiktra dynamo studi complet enrol indol non-
continu treatment double-refractori indol nhl refractori
rituximab chemotherapi radioimmunotherapi patient
follicular lymphoma fl small lymphocyt lymphoma sll
margin zone lymphoma mzl elig restrict
cytopenia primari endpoint best orr secondari endpoint
includ durat respons os safeti posit data
present oral present strengthen long-term
follow-up data present oral present
confer malign lymphoma icml eha meet
oct verastem corpor restructur wake defactinib
command trial verastem reduc headcount full time
copiktra grant fda track design double-
refractori follicular lymphoma fl follicular lymphoma materi
patient subset dynamo studi track design facilit
develop drug treat seriou condit fill unmet medic
need design help facilit verastem interact
agenc may help expedit on-going nda review process copiktra
fda ema orphan drug design indic
duvelisib miss autoimmun indic transit focu
oncolog phase aspira studi duvelisib
twice-daili plu methotrex week improv primari
endpoint versu placebo rheumatoid arthriti addit
duvelisib twice daili day improv
phase allergen challeng studi patient mild asthma copiktra
develop focu oncolog indic
defactinib io collabor bavencio ovarian cancer
phase trial evalu defactinib combin pfizer/merck kgaa
antibodi bavencio avelumab patient relapsed/refractori
ovarian cancer dose-escal portion enrol patient
determin recommend phase dose expans portion treat
patient phase dose primari endpoint safeti maximum
toler dose orr part surviv immune-bas respons metric
secondari endpoint accord clinicaltri gov full studi complet
washington univers initi phase trial defactinib
keytruda gemcitabin pancreat cancer investigator-initi
phase dose-escal studi enrol patient advanc
pancreat cancer primari endpoint recommend phase dose
secondari outcom safeti anti-tumor efficaci measur full
studi complet expect juli accord clinicaltri gov
preliminari data present see
turn pancreat cancer checkpoint immunotherapi
preclin studi publish jiang et al natur medicin conclud fak
inhibit may
import combin strategi checkpoint
inhibitor studi demonstr fak signal contribut fibrot
immun suppress tumor microenviron neoplast pancreat
ductal adenocarcinoma pdac cell fak inhibit
increas immun surveil pdac tumor alter product
pro-inflammatori immunosuppress cytokin make tumor
respons immunotherapi
sep abbvi termin copiktra collabor return right
infin multipl collabor includ purchas
pharmacycl ibrutinib imbruvica consider use front-
line cll partnership roch rhhbi rate venclexta
caus conflict ring fenc around collabor notifi
infin termin duvelisib collabor june top-
line data dynamo abbvie/infin agreement formal end
septemb year
verastem grab copiktra oncolog infin infin
perhap unprepar return copiktra burden materi
on-going infin look partner copiktra short time
complet transact verastem enter agreement infin
licens copiktra includ exclus world-wide right research
develop commerci manufactur copiktra-bas product
oncolog indic verastem paid infin million cash upon posit
phase data duo trial pay million cash stock
approv copiktra us intern verastem pay tier
mid-to-high single-digit royalti infin royalti infin cover
legaci agreement compound mundipharma privat
dec dynamo oral present verastem present
primari analysi phase dynamo studi oral present
follicular lymphoma fl cohort total serv basi
on-going nda review acceler approv double-refractori fl
patient orr includ orr fl patient pr
independ review meet primari endpoint orr
less evalu patient target lymph node reduct
independ review overal studi median durat respons
month respect independ review copiktra
consid well toler manag safeti profil presenc
appropri risk mitig accord flinn et al
dec contempo present preliminari data
phase contempo trial copiktra plu rituximab dr obinutuzumab
untreat fl patient present best orr
assess investig dr arm cr
arm cr safeti profil dr
consist previous character safeti copiktra monotherapi
accord casulo et al enrol onto studi
termin earli copiktra develop follicular lymphoma remain
focus double-refractori popul
data double-refractori follicular lymphoma verastem present long-
term follow-up data fl subset data dynamo oral
present icml eha meet comment gener relat
fl cohort orr fl patient improv includ cr
independ review investig assess median
durat respons month respect independ
review respons observ rapidli within median month
patient copiktra median month median os
month zinzani et al conclud copiktra remain well toler
demonstr favor benefit/risk profil double-refractori fl
copiktra grant fda track design peripher t-cell
lymphoma verastem initi phase studi copiktra assess
molecul efficaci safeti see track
design facilit develop drug treat seriou condit
fill unmet medic need design help facilit
verastem interact agenc design may help expedit
review process
defactinib phase combin keytruda launch cancer
research unit kingdom investigator-sponsor studi evalu
defactinib plu keytruda merck rate antibodi
patient refractori nsclc pancreat cancer mesothelioma
comer phase portion enrol cohort patient
expans cohort nsclc pancreat cancer mesothelioma enrol
patient pre-specified futil analys primari endpoint
safeti secondari outcom includ efficaci pk assess primari
complet expect may accord clinicaltri gov
sep verastem announc posit top line result phase
duo studi cll/sll posit top line data random
patient phase duo studi relapsed/refractori cll/sll demonstr
median month copiktra significantli greater
month ofatumumab hr blind independ
review committe key subpopul patient difficult treat
delet patient median vs month copiktra
oct fda provid construct guidanc copiktra regulatori
pathway verastem met fda receiv written feedback regard
copiktra nda strategi base guidanc verastem nda request full
approv copiktra treatment relapsed/refractori cll/sll
acceler approv treatment patient relapsed/refractori fl
dec copiktra phase duo data get oral present
american societi hematolog meet posit data
random phase duo studi relapsed/refractori cll/sll
discuss oral present signal
signific new treatment option later line cll patient patient
progress ofatumumab cross receiv copiktra
cross copiktra ofatumumab trial posit
primari endpoint see orr copiktra
ofatumumab per independ review copiktra patient
decreas lymph node burden baselin compar
treat ofatumumab
appear manag consist seen prior data
accord kol import consider copiktra potenti use
commun set given oral dose
dec copiktra phase combin data relapsed/refractori t-cell
lymphoma oral present investig memori sloan
ketter present result parallel dose-escal phase trial
evalu copiktra either romidepsin bortezomib relapsed/
refractori peripher cutan ctcl t-cell lymphoma
regimen achiev respons rate least
limit dose escal bortezomib
romidepsin evalu copiktra plu romidepsin plan
announc price million common share per share
aggreg net proce approxim million fund commerci
prepar launch cost copiktra
jan verastem increas debt facil million verastem
increas exist loan agreement hercul capit provid
million support regulatori commerci activ
copiktra on-going develop million remain avail
drawn upon sever tranch upon fda accept copiktra nda
condit
jan preclin data support copiktra io combin asco-
clinic immuno-oncolog symposium verastem patcher
weaver present preclin data support potenti copiktra
combin therapi co-stimulatori antibodi patient
 cell malign copiktra clinic activ monotherapi cell
malign addit inhibit known reduc immune-
suppress treg inhibit known reduc immunosuppress
efficaci checkpoint co-stimulatori antibodi anti-
antibodi support work io combin
patient cell malign well tumor type
feb copiktra nda submit verastem file copiktra nda full
approv copiktra treatment relaps refractori cll/sll
acceler approv treatment relapsed/refractori fl
advanc
hematolog malign publish blood open-label dose-
escal phase trial flinn et al evalu maximum toler dose
pharmacodynam respons efficaci safeti copiktra
patient advanc hematolog malign includ patient
dose-escal receiv twice daili patient
expans phase copiktra dose bid continu
studi identifi twice daili copiktra rapidli absorb
show dose-depend pharmacokinet profil safeti data inform
public underscor copiktra potenti cll/sll provid solid
evid support on-going nda tcl subset publish
horowitz et al support addit phase primo studi
initi copiktra phase brio studi cll/sll patient
evalu copiktra patient cll/sll relaps
refractori intoler prior btk therapi ibrutinib primari
endpoint orr secondari endpoint includ safeti durat respons
diseas control rate primari analysi expect june
accord clinicaltri gov posit expect data support
increas adopt patient follow btk therapi
initi copiktra phase primo studi peripher t-cell
primo studi evalu copiktra twice daili determin
optim dose relapsed/refractori peripher t-cell lymphoma
patient divers group aggress non-hodgkin lymphoma
dose select patient enrol onto expans phase
primari endpoint orr secondari endpoint includ safeti durat
respons diseas control rate os primari analysi expect
around novemb accord clinicaltri gov posit data could
support expand copiktra label
initi phase rockif studi defactinib carboplatin-
resist ovarian cancer univers san diego phase rockif trial
evalu defactinib re-sensit carboplatin-resist ovarian cancer
carboplatin paclitaxel single-arm trial enrol patient assess
safeti orr combin estim primari complet
septemb full studi complet anticip octob
accord clinicaltri gov view continu investig interest
defactinib combin trial support propos underli biolog
april copiktra nda accept fda prioriti review verastem
announc fda accept verastem copiktra nda april
establish octob pdufa action date fda accept copiktra
nda allow verastem begin materi ramp pre-commerci
june verastem present abstract copiktra
defactinib american societi clinic oncolog meet
june verastem present five poster focus copiktra defactinib
data highlight benefici effect copiktra dual inhibit
tumor microenviron suggest earli sign activ
pancreat cancer
june duvelisib partner yakult honsha co ltd japan
exclus licens agreement give yakult right duvelisib oncolog
indic japan verastem receiv million up-front elig
million develop commerci mileston double-digit
royalti yakult also fund certain global develop cost duvelisib
pro-rata basi partnership add level industri valid
previous describ data set present prioriti review
june verastem rais million verastem close regist sale
million share common stock per share conson
capit net proce offer approxim million help
fund pre-commerci copiktra
june copiktra show activ front line cll combo
european hematolog associ meet dr mathew david dana-
farber cancer institut present data investigator-sponsor trial
evalu potenti addit copiktra increas cure rate
fcr fludarabin cyclophosphamid rituximab frontlin set
younger cll patient high rate bone marrow mrd minimum residu
diseas neg achiev better histor fcr cohort
compar ibrutinib/fcr data accord investig high rate
bone marrow mrd neg achiev patient unmut ighv
associ poor prognosi fcr addit respons deepen
copiktra mainten follow complet fcr combin
toxic appear materi manag event compar either
agent alon accord david et al includ infecti immune-
mediat event well secondari malign conclus
dfcr effect regimen younger fit patient may desir chanc
long term remiss
septemb copiktra receiv fda approv cll/sll fl
fda approv copiktra ahead octob pdufa date trigger
million mileston payment infin payabl either cash stock drug
indic twice-daili treatment relapsed/refractori cll/sll
patient fail two prior line therapi relapsed/refractori fl
patient fail least two prior line therapi verastem launch
copiktra presenc sale rep district manag market access
profession medic scienc liaison view copiktra
conveni highly-act twice-daili oral therapi relapsed/refractori
cll/sll fl potenti indic
exhibit verastem recent import upcom event
septemb copiktra partner cspc pharmaceut group
limit china exclus licens agreement give cspc right
copiktra oncolog indic china hong kong macau taiwan
verastem receiv million up-front novemb elig
million develop commerci mileston double-
digit royalti million mileston relat develop
cspc also fund certain global develop cost copiktra pro-rata
basi partnership add level industri valid announc
day fda approv
phase data patient relapsed/refractori patient
ctcl treat duvelisib combin encourag unmet need
materi r/r orr current rang
orr duvelisib romidepsin
includ median month common grade
neutropenia diarrhea alt elev
verastem current enrol phase primo studi duvelisib
monotherapi r/r patient repres next potenti
copiktra approv data primo studi could avail
addit copiktra partnership addit
june japan partnership yakult septemb china deal
cspc potenti addit geographi verastem seek
partner copiktra retain materi econom addit upfront
mileston verastem potenti add addit non-dilut capit
verastem transit commerci entiti would expect potenti
partner becom aggress fda approv copiktra
addit copiktra combin studi addit june
eha data copiktra fcr fludarabin cyclophosphamid
rituximab frontlin set younger cll patient would expect
addit studi data public copiktra variou combin
regimen multipl addit set instanc dr mathew david
dana-farb cancer institut plan begin enrol phase trial
assess combin copiktra/venclexta r/r
cll/sll patient copiktra dose one week venclexta
ad primari endpoint trial dose combin
rate complet remiss studi enrol patient prior
exposur either agent
proof-of-concept defactinib io combin
sever on-going studi evalu defactinib combin io antibodi
bavencio keytruda verastem conduct phase trial
dateeventcommentsignificancesep duvelisib approv fdaverastem posit rapidli launch w/ approvalvvvvvsep partner up-front mileston double-digit duvelisib ou partnershipaddit region effort modest clinic proof-of-conceptposit data support expans effort maashould acceler partnership eu partnershippotenti materi upfrontsvvvv signific least import vvvvv import
bavencio ovarian cancer washington univers school
medicin cancer research unit kingdom conduct earli phase
trial keytruda advanc nsclc pancreat cancer
mesothelioma all-com phase data trial washington
univers evalu defactinib plu keytruda gemcitabin present
support expans pdac cohort
duvelisib file eu verastem expect updat plan
eu strategi later current assum verastem submit
duvelisib dossier ema potenti eu approv
copiktra basic copiktra twice-daili oral phosphoinositid
delta gamma enzym inhibitor copiktra first-in-class dual
inhibitor delta gamma isoform enzym known help
support growth surviv malign b-cell t-cell signal
may lead prolifer malign b- t-cell thought play
role format mainten tumor microenviron
molecul fda approv treatment relapsed/refractori cll/sll
prior therapi relapsed/refractori fl prior system
therapi base posit result phase duo phase
dynamo trial respect approv septemb ahead
oct pdufa date phase develop program on-going
copiktra inhibit signal pathway effect direct anti-canc
effect malign b-cell via isoform inhibit benefici anti-
cancer effect tumor microenviron via inhibit copiktra
fda track design approv indic
orphan drug design cll/sll us europ
flinn et al dynamo phase studi copiktra patient refractori indol non-hodgkin
biolog brief phosphatidylinositol famili
intracellular lipid kinas gener second messeng regul sever
downstream pathway critic normal cell growth prolifer
metabol addit diseas enzym major posit
major neg regul pathway regul
growth surviv prolifer exhibit famili divid
class ii depend upon code gene structur substrat
prefer class four member character accord
activ model class ia consist class ib
consist class ia heterodim consist
regulatori subunit catalyt subunit class ib compris
singl catalyt subunit associ regulatori
subunit wherea isoform show broad tissu distribut
highli express leukocyt control immun respons exhibit
among class studi
fundament physiolog patholog role
exhibit copiktra inhibit differenti
import signal compon frequent
mutat protein human cancer often result unregul
signal activ tumorigenesi ann pathol
malign curr opin pharma activ
pathogenesi malign
develop resist anti-cancer therapi inhibitor
consider promis therapi combin cytotox
biolog therapi well though remain fulli elucid
therapeut strategi focus modul pathway
potenti develop util biomark patient-specif mutat
profil maxim benefit combin import
complex signal make challeng target develop
cancer therapeut
preclin studi suggest specif pathway inhibitor may
imped tumor cell growth and/or induc apoptosi combin
pathway inhibitor chemotherapi attenu resist
pathway implic wide varieti respons
inhibit induc antitumor effect molecul design target specif
compon pathway develop clinic use singl
agent combin cytotox drug variou tumor type
addit character activ select inhibit isoform
demonstr promis
microenviron creat potenti
develop molecul
term modul
implic
exhibit signal pathway target cell
focu copiktra dual inhibit copiktra
believ directli attack malign b-cell t-cell also disrupt
tumor microenviron nearli exclus express
hematopoiet cell hyperact cell malign promot b-
cell prolifer growth surviv adhes home
locat
downstream variou b-cell receptor includ cell antigen receptor
bcr cytokine/chemokin receptor adhes molecul exhibit
pathway orchestr activ b-cell malign
upon bcr activ inhibit therefor demonstr activ
variou b-cell leukemia lymphoma intriguingli recent work
describ ali et al natur inhibit also shown
exhibit multipl role tumor growth surviv
david md mmsc et al phase ib/ii studi copiktra combin fcr dfcr frontlin
therapi younger cll patient
focu copiktra highli express myeloid cell
activ appear associ increas stabil tumor
microenviron activ restrain nfb activ promot
suppress factor tumor growth work keneda et al de henau
publish natur exhibit show effect inhibit
tumor immun suppress inhibit inhibit c/ebp stimul
lead express
nfb lead alter express pro-inflammatori immun respons
cytokin inhibit convert tumor-associ macrophag pro-
inflammatori macrophag promot cell respons
suppress tumor growth sum inhibit appear abl
reshap tumor immun microenviron promot tumor regress
exhibit gamma inhibit activ convert tumor associ macrophag pro-inflammatori
macrophag suppress tumor growth
keneda et al molecular switch control immun suppress natur
collect featur inhibit copiktra
summar work conduct verastem present asco-sitc
addit proven activ monotherapi patient cell
malign copiktra activ tumor microenviron result
greatli enhanc efficaci antibodi induc tumor
regress immun memori combin immune-oncolog
approach lymphoma model support explor
molecul io combin
exhibit copiktra delta gamma inhibit activ
 pacher weaver dual inhibitor copiktra reduc immunosuppress treg myeloid cell enhanc efficaci
checkpoint co-stimulatori antibodi cell lymphoma model asco-sitc clinic immuno-oncolog symposium
regulatori fda health agenc oversight compani whose
main busi drug develop verastem subject rigor
strenuou regulatori requir us food drug administr
fda intern medicin develop regulatori agenc
new drug approv market promot approv drug
product also regul fda relat agenc throughout globe
though compani specif focu ethic prescript pharmaceut
place signific risk oper believ risk time
greater less research-bas drug develop
compani biotechnology/biopharmaceut industri
materi depend upon copiktra success materi portion
verastem estim revenu cash profit estim come
develop copiktra oncolog drug approv fda monotherapi
treatment relapsed/refractori cll/sll fl line set
report copiktra clinic benefit efficaci safeti suffici satisfi
regulatori author fda ema larg anticip potenti
revenu cash profit expect result approv risk
could materi restrict compani sever way like materi
neg affect vstm share note valuat comment
copiktra develop program materi investor interest believ
repres materi portion verastem valuat therefor copiktra
commerci adopt progress effici label expans
effort materi risk vstm share could trade neg result
capit loss vstm sharehold
manufactur fda oversight fda quit vigil inspect
drug biolog manufactur plant us global
verastem and/or contract manufactur could therefor subject risk
fda manufactur meaning problem
verastem manufactur oper could materi potenti
product consequ could materi neg affect verastem
oper vstm share
reimburs risk patient physician insur may ascertain
benefit valu verastem brand therapeut benefici light
particular insur could requir rigor requir prior author
payment prescript approv manag care
significantli accept verastem product price arrang compani
revenu could insuffici obtain profit vstm sharehold
could experi neg return result
commerci risk copiktra particip highli competit market
exist develop stage therapeut verastem recent
establish market capabl compani unabl achiev
signific product sale necessari profit vstm share could
materi harm also verastem fail obtain intern commerci
partner product vstm share could also significantli harm
financ risk vstm share may subject financ risk compani
may need rais addit capit support commerci launch
copiktra cll/sll fl may need rais addit fund complet
studi indic copiktra and/or opportun
pipelin verastem unabl obtain licensur us addit
intern market product unabl suffici differenti
compar gener brand option indic
pursu materi addit dilut exist sharehold possibl
investor percept vstm share could substanti harm
addit risk verastem incur expect incur signific cost
result law regul relat corpor govern
matter verastem subject feder state foreign healthcar law
regul implement chang healthcar law
regul could advers affect busi result oper
exhibit copiktra npv cll/sll
 us royalti royalty- total upfront/milestones- total revenu verastem- verastem expens cog us royalti royalti cog total expense- net verastem- rate tax effect rate total per valu npv/share
exhibit copiktra npv fl
 us royalti royalty- upfront/milestones- total revenu verastem- verastem expens cog us royalti royalti cog total expense- net verastem- rate tax effect rate total per valu npv/share
exhibit copiktra npv
 us royalti royalty- milestones- total revenu verastem- verastem expens cog us royalti royalti cog sg a- total expense- net verastem- day rate tax effect rate total per valu npv/share
verastem statement except per share amt product revenu duvelisib total us defactinib total us other/collab proprietari drug revenu verastem us mileston royalti revenu royalti partners- up-front mileston partners- total roylti upfnt milestn payments- revenue- total verastem revenue- expens amort acquir intang oper marginnmnmnmnmnmnmnmnmnmnmnm interest interest incom financ incom incom pre-tax tax tax tax convert prefer secur transact net incom loss effect fulli marginnmnmnmnmnmnmnmnmnmnmnmoth comprehens incom comprehens incom ex-charg eff ex-charg comprehens incom eff o/ o/ expens sale -- sale product year year growth -- incomenmnmnmnmnmnmnmnmnmnmnmpretax incomenmnmnmnmnmnmnmnmnmnmnmnet incomenmnmnmnmnmnmnmnmnmnmnmep ex-charg nmnmnmnmnmnmnmnmnmnmnmep ex-charg fully-tax nmnmnmnmnmnmnmnmnmnmnmsourc verastem inc sec document btig estim contact inform robert bert hazlett manag director btig research
verastem balanc sheet statement flow except per share amount
 investments/mktb account receiv prepaid current current properti equip intang asset restrict total account accru current current convert note non-curr long-term equiti common addit paid accumul comprehens accumul equiti sharehold total liabil sharehold statement oper activ net incom depreci amort acquir intang non-cash compens amort avail sale account inventori prepaid expens current account accru expens oper oper invest activ capit expenditur purchas matur invest financ activ defer financ proce iss common stock proceeds/retir convert note use settl restrict stock financ cash increas decreas cash rest verastem inc sec document btig estim contact inform robert bert hazlett manag director btig research
btig cover compani mention report
robert hazlett herebi certifi view compani secur discuss report
accur express receiv receiv direct indirect compens exchang
express specif recommend view report
jame colbi herebi certifi view compani secur discuss report
accur express receiv receiv direct indirect compens exchang
express specif recommend view report
